Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy

Lupus. 1997;6(4):412-4. doi: 10.1177/096120339700600413.

Abstract

The pathogenesis and therapy of shrinking lungs syndrome in patients with systemic lupus erythematosus remains controversial. It has been previously reported that corticosteroid treatment can be effective. We report a patient with shrinking lungs syndrome who presented a good response to inhaled beta-agonist therapy. Therapeutic approach to this syndrome is discussed.

Publication types

  • Case Reports

MeSH terms

  • Administration, Inhalation
  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / therapeutic use*
  • Adult
  • Albuterol / administration & dosage
  • Albuterol / therapeutic use*
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Diseases / drug therapy*
  • Lung Diseases / etiology*
  • Lung Diseases / physiopathology
  • Lupus Erythematosus, Systemic / complications*
  • Lupus Erythematosus, Systemic / physiopathology
  • Pulmonary Ventilation
  • Radiography, Thoracic
  • Tomography, X-Ray Computed

Substances

  • Adrenergic beta-Agonists
  • Bronchodilator Agents
  • Albuterol